| Current Price | $30.92 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $30.60 | P/E Ratio | 0.00 |
| Prev. Close | $30.39 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $30.11 - $31.13 | Volume | 1,141,004 |
| 52-Wk Range | $19.00 - $31.78 | Avg. Daily Vol. | 877,274 |
| Current Price | $30.92 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $30.60 | P/E Ratio | 0.00 |
| Prev. Close | $30.39 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $30.11 - $31.13 | Volume | 1,141,004 |
| 52-Wk Range | $19.00 - $31.78 | Avg. Daily Vol. | 877,274 |
The best Bull and Bear pitches based on recency and number of recommendations.
Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.
Read the most recent pitches from players about EDIT.
Recs
SurfingCabarete
(29.92)
Submitted: 7/9/2019 12:17:57 PM :
Start Price:
$23.84
NASDAQ:EDIT Score:
+23.61
bet on gene editing
Recs
WilliamEbonics
(62.04)
Submitted: 5/20/2019 5:28:14 PM :
Start Price:
$22.17
NASDAQ:EDIT Score:
-29.31
The Stock continues a downward drift, while money also continues to exit the stock over an extended period of time.
Recs
MarkFitzFool
(46.43)
Submitted: 5/11/2019 3:08:22 PM :
Start Price:
$24.45
NASDAQ:EDIT Score:
+14.98
It's been a bumpy ride for Editas over the past few years, but such is the nature of being a developmental stage biotech company. What sets Editas apart is their leadership. Feng Zhang, one of the developers of both CRISPR and optogenetics, is a co-founder, as is George Church, one of the most famous scientists in the world and a pioneer of both synthetic biology and personalized genomics. Editas is early-stage, and inherently risky, but I'm extremely confident that they will prevail. They have a robust developmental and preclinical pipeline with therapies for Beta-Thalassemia, Sickle Cell, DMD, Cystic Fibrosis, genetic diseases of the eye and liver, CAR-T for cancer therapy, etc. Will they be the first to market with one of their cutting-edge non-CAR-T gene-editing therapies? Likely not (I think bluebird bio will beat them), but they have many promising shots on goal that position them to be a leader in the space. Furthermore, The Broad Institute holds several CRISPR patents, and both Zhang and Church are members of said institute. I foresee Editas being one the future's top companies for personalized genetic therapies.
Find the members with the highest scoring picks in EDIT.
PAGEBOY73 (99.26) Score: +120.59
The Score Leader is the player with the highest score across all their picks in EDIT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| SeriousK | 28.85 | 3/9/2016 |
|
5Y | $42.70 | -27.59% | +57.93% | +85.52 | 0 Comment | |
| freemarketmike | < 20 | 6/7/2017 |
|
5Y | $15.43 | +100.35% | +29.28% | +71.07 | 1 Comment | |
| WoollyWombat | < 20 | 9/16/2016 |
|
5Y | $14.48 | +113.54% | +47.57% | +65.97 | 0 Comment | |
| FunesDMemorious | 97.89 | 10/26/2016 |
|
5Y | $14.55 | +112.51% | +47.67% | +64.84 | 0 Comment | |
| portefeuille | 98.38 | 2/10/2016 |
|
5Y | $13.26 | +133.18% | +68.85% | +64.33 | 0 Comment | |
| CMFMLove | 43.16 | 6/13/2017 |
|
5Y | $16.00 | +93.25% | +29.05% | +64.20 | 1 Comment | |
| Playa14 | < 20 | 6/9/2017 |
|
5Y | $16.08 | +92.29% | +28.99% | +63.30 | 0 Comment | |
| portefeuille2 | 99.12 | 9/22/2016 |
|
5Y | $14.87 | +107.94% | +45.11% | +62.82 | 0 Comment | |
| TimeToBuy | 88.29 | 3/10/2016 |
|
5Y | $32.50 | -4.86% | +57.46% | +62.32 | 0 Comment | |
| forcel0 | 90.82 | 11/23/2016 |
|
5Y | $15.60 | +98.21% | +43.08% | +55.12 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
